Black patients wait a year longer for kidneys because they are referred to transplant centers after starting dialysis instead of before, and the waitlist clock only starts at referral

A kidney transplant patient's waitlist clock begins when they are listed at a transplant center, not when they first develop kidney failure. The medically optimal path is preemptive referral — getting on the waitlist before starting dialysis — because every month on dialysis degrades the body and worsens post-transplant outcomes. Over 90% of Black patients are referred to transplant centers only after they have already started dialysis, compared to a significantly higher preemptive referral rate for White patients. Primary care and specialty physicians identify White patients as good candidates for transplant more often than they do Black patients, and Black patients are half as likely to be placed on the waitlist as White patients. So what? Because waitlist position is determined partly by accrued waiting time, late referral means Black patients start their waitlist clock later, even though their kidneys may have been failing for just as long. The result: Black patients face wait times that are, on average, a full year longer than White patients. This is compounded by the now-corrected but historically devastating eGFR race coefficient, which until 2021 inflated kidney function estimates for Black patients by 16-21%, masking severe kidney disease and further delaying referral and listing. So what? Each additional year on dialysis costs approximately $90,000, destroys cardiovascular health, and reduces post-transplant graft survival. Black Americans make up 13% of the U.S. population but over 33% of the kidney transplant waitlist — a disparity driven not by biology but by systematic delays at every step: later diagnosis, later referral, later listing. The OPTN has attempted to remedy the eGFR damage by backdating wait times for affected patients, but this only partially addresses a problem rooted in referral patterns, physician bias, and structural barriers to accessing transplant centers. This problem persists because the referral pipeline is decentralized and unregulated. No federal policy requires nephrologists to refer patients for transplant evaluation at a specific eGFR threshold. Each physician makes an individual judgment call, and implicit bias in those calls compounds across millions of clinical encounters. CMS's Increasing Organ Transplant Access Model attempts to address this by incentivizing transplant hospitals to identify underserved populations, but it is voluntary and does not reach the referring physicians who control the pipeline's entry point.